Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/30/2008WO2008131439A1 Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
10/30/2008WO2008131419A2 Glycoconjugates of rna interference agents
10/30/2008WO2008131411A2 Stimulating neuronal growth using brevetoxins
10/30/2008WO2008131368A2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders
10/30/2008WO2008131354A2 Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
10/30/2008WO2008131340A1 Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
10/30/2008WO2008131320A1 Stilbene derivatives as new cancer therapeutic agents
10/30/2008WO2008131276A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
10/30/2008WO2008131267A2 Low calcemic, highly antiproliferative, analogs of calcitriol
10/30/2008WO2008131259A1 Deuterated morpholinyl compounds
10/30/2008WO2008131256A1 Improved treatments for premature ejaculation in humans
10/30/2008WO2008131253A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
10/30/2008WO2008131227A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
10/30/2008WO2008131219A1 Substituted anthranilic acids
10/30/2008WO2008131149A2 Crystal forms of saxagliptin and processes for preparing same
10/30/2008WO2008131148A1 Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
10/30/2008WO2008131123A1 Recognitive hydrogel
10/30/2008WO2008131117A1 Lipoic acid derivatives
10/30/2008WO2008131114A2 Pharmaceutical formulations containing lipoic acid derivatives
10/30/2008WO2008131103A2 Drug discovery methods for aurora kinase inhibitors
10/30/2008WO2008131074A1 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
10/30/2008WO2008131062A2 Process for preparing capecitabine
10/30/2008WO2008131059A2 Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
10/30/2008WO2008131057A2 Sustained release formulations of opioid and nonopioid analgesics
10/30/2008WO2008131056A2 Sustained release monoeximic formulations of opioid and nonopioid analgesics
10/30/2008WO2008131050A1 Pyrrolotriazine kinase inhibitors
10/30/2008WO2008131006A2 Method for inhibiting scavenger receptor-a and increasing immune response to antigens
10/30/2008WO2008131000A2 7-substituted indole mcl-1 inhibitors
10/30/2008WO2008130970A1 7-nonsubstituted indole mcl-1 inhibitors
10/30/2008WO2008130953A2 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
10/30/2008WO2008130951A1 Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
10/30/2008WO2008130944A1 Solid phase syntheses of amino pyrimidine compounds
10/30/2008WO2008130902A1 Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
10/30/2008WO2008130879A2 Tetrahydroindole and tetrahydroindazole derivatives
10/30/2008WO2008130853A1 Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
10/30/2008WO2008130718A1 Sulfonamide containing compounds for treatment of inflammatory disorders
10/30/2008WO2008130669A1 Benzimidazoles and pharmaceutical compositions thereof
10/30/2008WO2008130650A1 Thermal responsive polymer siloxanes, compositions, and methods and applications related thereto
10/30/2008WO2008130640A1 Implants for the treatment of psychiatric states
10/30/2008WO2008130637A1 Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
10/30/2008WO2008130632A2 Methods of increasing camp levels and uses thereof
10/30/2008WO2008130630A2 Polymorphic form of rimonabant hydrochloride and processes for preparation thereof
10/30/2008WO2008130616A2 Diaryl morpholines as cb1 modulators
10/30/2008WO2008130615A1 Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
10/30/2008WO2008130600A2 Quinolones and azaquinolones that inhibit prolyl hydroxylase
10/30/2008WO2008130584A1 Pyrimidinone derivatives and methods of use thereof
10/30/2008WO2008130581A1 Pyrimidinone derivatives and methods of use thereof
10/30/2008WO2008130570A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
10/30/2008WO2008130569A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
10/30/2008WO2008130552A1 Triazole derivatives which are smo antagonists
10/30/2008WO2008130534A1 Crystalline forms of topotecan hydrochloride and processes for making the same
10/30/2008WO2008130527A1 Novel 1,8-naphthyridine compounds
10/30/2008WO2008130524A1 Aryl heterocyclic cgrp receptor antagonists
10/30/2008WO2008130520A1 Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
10/30/2008WO2008130515A1 Anti-cancer agents, compositions and methods of treating cancers
10/30/2008WO2008130514A1 Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
10/30/2008WO2008130512A1 Bicyclic anilide heterocyclic cgrp receptor antagonists
10/30/2008WO2008130508A1 Indanone derivatives that inhibit prolyl hydroxylase
10/30/2008WO2008130481A1 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
10/30/2008WO2008130449A2 Modulators of amyloid-beta production
10/30/2008WO2008130395A2 Desferrithiocin analogue actinide decorporation agents
10/30/2008WO2008130370A1 Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
10/30/2008WO2008130368A2 Transcription factor modulating compounds and methods of use thereof
10/30/2008WO2008130332A1 Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use
10/30/2008WO2008130323A1 Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain
10/30/2008WO2008130322A1 Novel 5-heterocyclyl-chromane derivatives for the treatment of pain
10/30/2008WO2008130321A2 Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
10/30/2008WO2008130320A2 Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
10/30/2008WO2008130314A1 Xanthine compounds having a positive allosteric gabab receptor modulator effect
10/30/2008WO2008130313A1 Imidazole derivatives as modulators of the gaba receptor for the treatment of gastrointestinal disorders
10/30/2008WO2008130312A1 A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701
10/30/2008WO2008130296A1 Binding of pathological forms of proteins using conjugated polyelectrolytes
10/30/2008WO2008130261A1 Treatment of infections by carbon monoxide
10/30/2008WO2008130234A1 High dose composition of ursodeoxycholic acid
10/30/2008WO2008130216A1 Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
10/30/2008WO2008130172A1 N- hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same
10/30/2008WO2008130151A1 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
10/30/2008WO2008130137A1 Anionic lipid nanosphere and preparation method of the same
10/30/2008WO2008129994A1 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
10/30/2008WO2008129980A1 Particulate composition comprising reduced coenzyme q10, and method for production thereof
10/30/2008WO2008129971A1 Improved persistently infective sendai virus vector
10/30/2008WO2008129951A1 Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
10/30/2008WO2008129874A1 Method of targeting tumor cell and use of the same
10/30/2008WO2008129846A1 Pharmaceutical composition
10/30/2008WO2008129624A1 Pyrazolopyridine-4-yl-pyrazolone derivative, addition salt thereof and phosphodiesterase inhibitor containing the same as active ingredient
10/30/2008WO2008129607A1 Hyaluronan production accelerator and hyaluronan decomposition suppressant
10/30/2008WO2008129562A2 An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof
10/30/2008WO2008129530A1 Gemcitabine production process
10/30/2008WO2008129529A2 Cannabinoid for the treatment of neuronal damage in diabetic patients
10/30/2008WO2008129517A2 A stabilized delayed release pharmaceutical composition of rabeprazole
10/30/2008WO2008129507A1 Controlled release multiple layer coatings
10/30/2008WO2008129501A2 Pharmaceutical compositions of duloxetine
10/30/2008WO2008129396A2 Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
10/30/2008WO2008129380A1 Sulfonyl amide derivatives for the treatment of abnormal cell growth
10/30/2008WO2008129319A1 Salts of oxadiazole derivatives as dgat inhibitors
10/30/2008WO2008129318A2 A foam material for medical use and method for producing same
10/30/2008WO2008129308A2 Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
10/30/2008WO2008129303A2 Sustained release
10/30/2008WO2008129288A2 Disulfonamides useful in the treatment of inflammation
10/30/2008WO2008129280A1 Pyrazoles useful in the treatment of inflammation
1 ... 3015 3016 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 3030 3031 3032 3033 3034 3035 ... 7860